ClinicalTrials.gg
Not yet recruitingNCT07311811Updated Dec 31, 2025

A Study to Evaluate the Pharmacokinetics and Safety of IN-M00007 and IN-R00007 in Healthy Adult Volunteers

A Phase 1 interventional study of IN-R00007 and IN-M00007 in Healthy Volunteers, sponsored by HK inno.N Corporation. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years to 59 Years
Sex
All
01

Study summary

This study aims to evaluate the Pharmacokinetic (PK) characteristics and safety after a single oral dose administration of IN-M00007 and IN-R00007 in healthy adult volunteers

Read the detailed description

An open label, randomized, single oral dose, crossover study

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult volunteers aged ≥ 19 and \< 60 years at screening
  2. (BMI) in the range of 18.0 and 30.0 kg/㎡

    • Body weight ≥ 50kg for male
    • Body weight ≥ 45kg for female
  3. Subjects who do not have significant congenital or chronic diseases and without pathological symptoms or findings based on medical examinations(if necessary, EEG, , chest X-ray, gastroscopy or gastrointestinal radiographic tests)
  4. Determined by the investigator to be eligible for study participation based on the results of screening tests (e.g. hematology test, blood chemistry test, serology test, urinalysis, pregnancy diagnostic tests) conducted according to the IP characteristics
  5. Subjects who voluntarily signed the consent form after receiving detailed explanation and understanding about purpose, details, characteristics of the IP and anticipated adverse events of the study
  6. Subjects who agree to use highly effective methods of (excluding hormonal methods) to preclude the possibility of pregnancy of themselves or their spouse/partner from the first IP administration until 14 days after the last administration, and who agrees not to donate sperm or ovum during this period

    • Highly effective contraceptive methods: intrauterine device(IUD), bilateral tubal ligation, a partner who has undergone vasectomy, or sexual abstinence However, periodic abstinence(calendar method, symptothermal method, post-ovulation method), withdrawal intercourse(coitus interruptus), spermicide methods, lactational amenorrhea method, and simultaneous use of female and male condoms are not considered contraceptive methods

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have taken drugs which can induce(e.g, Barbiturates) or inhibit drug metabolism enzyme within 30 days prior to the start of the study(first IP administration day) or have taken medications that may affect this study within 10 days prior to the start of the study(first IP administration day)
  2. Subjects who have participated in any other clinical study or bioequivalence study and administered IP within 6 months
  3. Subjects who have donated whole blood within 8 weeks prior to the start of the study(first IP administration day) or have donated component blood within 2 weeks prior to the start of the study(first IP administration day)
  4. Subjects with a history of gastrointestinal resection that may affect drug absorption(excluding appendectomy and hernia operation)
  5. Subjects meeting following conditions within 1 month prior to the start of the study(first IP administration day)

    • Alcohol consumption > 21 glasses per week for male
    • Alcohol consumption > 14 glasses per week for female
  6. Subjects with the following diseases

    • Subjects with to the ingredient or components of this drug
    • Subjects with active liver disease or those with persistently elevated serum aminotransferase levels of unknown cause
    • Subjects with muscular disorders
    • Subjects receiving concomitant administration with cyclosporine
    • Subjects with severe renal impairment or kidney dysfunction
    • Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  7. Subjects with a history of mental illness
  8. Pregnant or breastfeeding women if female
  9. Subjects who are judged ineligible for the clinical study by the investigator due to reasons other than the above inclusion/exclusion criteria
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Sequence A

    R → T R: IN-R00007, T: IN-M00007

    Drug: IN-R00007 · Drug: IN-M00007

  • Experimental
    Sequence B

    T → R R: IN-R00007, T: IN-M00007

    Drug: IN-R00007 · Drug: IN-M00007

Interventions

  • DrugIN-R00007

    Single dose

  • DrugIN-M00007

    Single dose

06

What researchers measure

Primary outcomes

  1. PK parameter

    AUCt of Rosuvastatin

    Time frame: Up to 48 hours

  2. PK parameter

    Cmax of Rosuvastatin

    Time frame: Up to 48 hours

  3. PK parameter

    AUCt of Ezetimibe

    Time frame: Up to 72 hours

  4. PK marameter

    Cmax of Ezetimibe

    Time frame: up to 72 hours

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Mar 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Dec 31, 2025
StartEst.
Jan 2026
Primary completionEst.
Mar 2026
CompletionEst.
Apr 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07311811
Responsible party
Sponsor
First posted
Dec 31, 2025
Start date
Jan 2026 (estimated)
Primary completion
Mar 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

Heeju Ahn
Contact
heeju.ahn21@inno-n.com
+82 31-5176-4662
Yugyeong Park
Contact
yugyeong.park@inno-n.com
+82 31-5176-4661
Hyeonggeon Kim
principal investigator · H Plus Yangji Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion